144 related articles for article (PubMed ID: 24799493)
21. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
[TBL] [Abstract][Full Text] [Related]
22. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
Yáñez R; Barrios Y; Ruiz E; Cabrera R; Díaz-Espada F
J Immunother; 2008 Apr; 31(3):310-2. PubMed ID: 18317357
[TBL] [Abstract][Full Text] [Related]
23. Vaccination strategies in follicular lymphoma.
Kannan S; Neelapu SS
Curr Hematol Malig Rep; 2009 Oct; 4(4):189-95. PubMed ID: 20425407
[TBL] [Abstract][Full Text] [Related]
24. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
Bendandi M; Gocke CD; Kobrin CB; Benko FA; Sternas LA; Pennington R; Watson TM; Reynolds CW; Gause BL; Duffey PL; Jaffe ES; Creekmore SP; Longo DL; Kwak LW
Nat Med; 1999 Oct; 5(10):1171-7. PubMed ID: 10502821
[TBL] [Abstract][Full Text] [Related]
25. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor.
Liu HM; Newbrough SE; Bhatia SK; Dahle CE; Krieg AM; Weiner GJ
Blood; 1998 Nov; 92(10):3730-6. PubMed ID: 9808567
[TBL] [Abstract][Full Text] [Related]
26. Active idiotypic vaccination in a patient with biclonal follicular lymphoma.
Barrios Y; Plaza A; Cabrera R; Yáñez R; Suárez E; Fernández MN; Díaz-Espada F
Cancer Immunol Immunother; 2001 Apr; 50(2):87-92. PubMed ID: 11401030
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic lymphoma vaccines: importance of T-cell immunity.
Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
Schuster SJ; Neelapu SS; Gause BL; Janik JE; Muggia FM; Gockerman JP; Winter JN; Flowers CR; Nikcevich DA; Sotomayor EM; McGaughey DS; Jaffe ES; Chong EA; Reynolds CW; Berry DA; Santos CF; Popa MA; McCord AM; Kwak LW
J Clin Oncol; 2011 Jul; 29(20):2787-94. PubMed ID: 21632504
[TBL] [Abstract][Full Text] [Related]
29. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure.
Longo DL
J Natl Cancer Inst; 2006 Sep; 98(18):1263-5. PubMed ID: 16985240
[No Abstract] [Full Text] [Related]
30. Translational development of active immunotherapy for hematologic malignancies.
Kwak LW
Semin Oncol; 2003 Jun; 30(3 Suppl 8):17-22. PubMed ID: 12881808
[TBL] [Abstract][Full Text] [Related]
31. Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccine.
Ansell SM; Suman VJ
J Clin Oncol; 2011 Jul; 29(20):2748-9. PubMed ID: 21632499
[No Abstract] [Full Text] [Related]
32. Idiotype vaccination as consolidation therapy: time for integration into standard of care for follicular lymphoma?
Schuster SJ; Neelapu SS; Santos CF; Popa-McKiver MA; McCord AM; Kwak LW
J Clin Oncol; 2011 Dec; 29(36):4845-6. PubMed ID: 22042953
[No Abstract] [Full Text] [Related]
33. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
Kwak LW; Young HA; Pennington RW; Weeks SD
Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10972-7. PubMed ID: 8855293
[TBL] [Abstract][Full Text] [Related]
34. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
[TBL] [Abstract][Full Text] [Related]
35. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
[TBL] [Abstract][Full Text] [Related]
36. The role of idiotype vaccines in the treatment of human B-cell malignancies.
Bendandi M
Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
[TBL] [Abstract][Full Text] [Related]
37. Personalized vaccine for newly diagnosed follicular non-Hodgkin's lymphoma.
Clin Adv Hematol Oncol; 2003 Jan; 1(1):66. PubMed ID: 16227965
[No Abstract] [Full Text] [Related]
38. The current status of vaccine development in colorectal cancer.
Chang DZ
Clin Adv Hematol Oncol; 2007 Feb; 5(2):109-11, 136. PubMed ID: 17344798
[No Abstract] [Full Text] [Related]
39. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
Inogès S; Rodrìguez-Calvillo M; Zabalegui N; Lòpez-Dìaz de Cerio A; Villanueva H; Soria E; Suárez L; Rodríguez-Caballero A; Pastor F; García-Muñóz R; Panizo C; Pèrez-Calvo J; Melero I; Rocha E; Orfao A; Bendandi M; ;
J Natl Cancer Inst; 2006 Sep; 98(18):1292-301. PubMed ID: 16985248
[TBL] [Abstract][Full Text] [Related]
40. Intraclonal variability of VH genes in follicular lymphoma patients who have received anti-idiotypic immunotherapy.
Yáñez R; Barrios Y; Cabrera R; Díaz-Espada F
J Immunother; 2006; 29(1):61-6. PubMed ID: 16365601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]